Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of GBT021601 in adults and children with sickle cell disease
PACTR202208531640912Phase 2Not yet recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2 trial of osivelotor in sickle cell disease (SCD) (3 arms), sponsored by Global Blood Therapeutics. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202208531640912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202208531640912.